Shanghai Invo Biotechnology

Shanghai Invo Biotechnology is a clinical-stage biopharmaceutical company dedicated to the development of innovative gene therapies using its proprietary AAV technology. The company utilizes a high-throughput AAV capsid engineering platform to design viral vectors with enhanced tissue specificity and reduced pre-existing immunity. Its primary focus is on ophthalmology, with its lead candidate IVO-101 currently in clinical trials for neovascular age-related macular degeneration and diabetic macular edema. Beyond ophthalmology, Invo Biotechnology is expanding its pipeline into central nervous system and metabolic diseases. The company aims to provide transformative, one-time treatments that significantly improve patient outcomes and quality of life. Headquartered in Shanghai, it is backed by prominent life science investors including Lilly Asia Ventures and Qiming Venture Partners.